S&P 500   3,848.85 (-0.08%)
DOW   31,143.85 (-0.14%)
QQQ   325.33 (+0.48%)
AAPL   135.77 (+2.83%)
MSFT   225.04 (+0.31%)
FB   271.71 (+1.58%)
GOOGL   1,907.70 (+1.47%)
AMZN   3,323.37 (+1.84%)
TSLA   846.09 (-0.51%)
NVDA   543.04 (+1.57%)
BABA   259.97 (-2.08%)
CGC   33.42 (-0.62%)
GE   11.16 (-2.02%)
MU   83.47 (-0.04%)
AMD   89.72 (+1.09%)
NIO   57.68 (-0.05%)
T   28.90 (-0.21%)
F   11.72 (+7.92%)
ACB   11.03 (-4.42%)
BA   207.66 (-1.79%)
DIS   171.53 (-1.22%)
NFLX   571.92 (-2.46%)
GILD   66.94 (-1.54%)
S&P 500   3,848.85 (-0.08%)
DOW   31,143.85 (-0.14%)
QQQ   325.33 (+0.48%)
AAPL   135.77 (+2.83%)
MSFT   225.04 (+0.31%)
FB   271.71 (+1.58%)
GOOGL   1,907.70 (+1.47%)
AMZN   3,323.37 (+1.84%)
TSLA   846.09 (-0.51%)
NVDA   543.04 (+1.57%)
BABA   259.97 (-2.08%)
CGC   33.42 (-0.62%)
GE   11.16 (-2.02%)
MU   83.47 (-0.04%)
AMD   89.72 (+1.09%)
NIO   57.68 (-0.05%)
T   28.90 (-0.21%)
F   11.72 (+7.92%)
ACB   11.03 (-4.42%)
BA   207.66 (-1.79%)
DIS   171.53 (-1.22%)
NFLX   571.92 (-2.46%)
GILD   66.94 (-1.54%)
S&P 500   3,848.85 (-0.08%)
DOW   31,143.85 (-0.14%)
QQQ   325.33 (+0.48%)
AAPL   135.77 (+2.83%)
MSFT   225.04 (+0.31%)
FB   271.71 (+1.58%)
GOOGL   1,907.70 (+1.47%)
AMZN   3,323.37 (+1.84%)
TSLA   846.09 (-0.51%)
NVDA   543.04 (+1.57%)
BABA   259.97 (-2.08%)
CGC   33.42 (-0.62%)
GE   11.16 (-2.02%)
MU   83.47 (-0.04%)
AMD   89.72 (+1.09%)
NIO   57.68 (-0.05%)
T   28.90 (-0.21%)
F   11.72 (+7.92%)
ACB   11.03 (-4.42%)
BA   207.66 (-1.79%)
DIS   171.53 (-1.22%)
NFLX   571.92 (-2.46%)
GILD   66.94 (-1.54%)
S&P 500   3,848.85 (-0.08%)
DOW   31,143.85 (-0.14%)
QQQ   325.33 (+0.48%)
AAPL   135.77 (+2.83%)
MSFT   225.04 (+0.31%)
FB   271.71 (+1.58%)
GOOGL   1,907.70 (+1.47%)
AMZN   3,323.37 (+1.84%)
TSLA   846.09 (-0.51%)
NVDA   543.04 (+1.57%)
BABA   259.97 (-2.08%)
CGC   33.42 (-0.62%)
GE   11.16 (-2.02%)
MU   83.47 (-0.04%)
AMD   89.72 (+1.09%)
NIO   57.68 (-0.05%)
T   28.90 (-0.21%)
F   11.72 (+7.92%)
ACB   11.03 (-4.42%)
BA   207.66 (-1.79%)
DIS   171.53 (-1.22%)
NFLX   571.92 (-2.46%)
GILD   66.94 (-1.54%)
Log in
NASDAQ:NVAX

Novavax Stock Forecast, Price & News

$126.52
+1.47 (+1.18 %)
(As of 01/21/2021 12:09 PM ET)
Add
Compare
Today's Range
$122.80
Now: $126.52
$129.60
50-Day Range
$111.51
MA: $122.98
$131.75
52-Week Range
$6.26
Now: $126.52
$189.40
Volume28,976 shs
Average Volume3.34 million shs
Market Capitalization$8.05 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.01
Novavax, Inc., together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate that in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase III clinical trial for treating seasonal influenza in older adults. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, and the immune systems attack against microorganisms, as well as to allow immunization with much lower doses of antigen. The company is also developing RSV F vaccine for older adults (60 years and older) that is in Phase II clinical trial, as well as for healthy children between six months to five years of age that is in Phase I clinical trial. In addition, it develops nanoparticle vaccine candidates for clinic testing against ebola virus that is in Phase I clinical trial; and combination respiratory vaccine to protect against influenza and RSV. Further, the company is developing COVID-19 vaccine for coronavirus that causes pneumonia-like symptoms, which is in preclinical stage. It has a partnership agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.
Novavax logo

MarketRank

Overall MarketRank

1.58 out of 5 stars

Medical Sector

318th out of 1,926 stocks

Biological Products, Except Diagnostic Industry

37th out of 177 stocks

Analyst Opinion: 3.4Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:NVAX
CUSIP67000210
Phone240-268-2000
Employees522

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$18.66 million
Book Value($5.75) per share

Profitability

Net Income$-132,690,000.00
Net Margins-133.10%

Miscellaneous

Market Cap$8.05 billion
Next Earnings Date3/10/2021 (Estimated)
OptionableOptionable
$126.52
+1.47 (+1.18 %)
(As of 01/21/2021 12:09 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NVAX News and Ratings via Email

Sign-up to receive the latest news and ratings for NVAX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Novavax (NASDAQ:NVAX) Frequently Asked Questions

How has Novavax's stock been impacted by Coronavirus (COVID-19)?

Novavax's stock was trading at $10.51 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, NVAX stock has increased by 1,111.4% and is now trading at $127.32.
View which stocks have been most impacted by COVID-19
.

Is Novavax a buy right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novavax in the last year. There are currently 1 sell rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Novavax stock.
View analyst ratings for Novavax
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Novavax?

Wall Street analysts have given Novavax a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Novavax wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Novavax's CEO?

1,428 employees have rated Novavax CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 59% among Novavax's employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Novavax's next earnings date?

Novavax is scheduled to release its next quarterly earnings announcement on Wednesday, March 10th 2021.
View our earnings forecast for Novavax
.

How were Novavax's earnings last quarter?

Novavax, Inc. (NASDAQ:NVAX) issued its quarterly earnings data on Monday, November, 9th. The biopharmaceutical company reported ($3.21) earnings per share for the quarter, missing analysts' consensus estimates of $2.36 by $5.57. The biopharmaceutical company earned $157 million during the quarter, compared to the consensus estimate of $230.56 million. Novavax had a negative net margin of 133.10% and a negative return on equity of 1,346.17%. The business's revenue for the quarter was up 6180.0% compared to the same quarter last year.
View Novavax's earnings history
.

When did Novavax's stock split? How did Novavax's stock split work?

Novavax shares reverse split before market open on Friday, May 10th 2019. The 1-20 reverse split was announced on Wednesday, May 8th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 9th 2019. An investor that had 100 shares of Novavax stock prior to the reverse split would have 5 shares after the split.

What price target have analysts set for NVAX?

7 Wall Street analysts have issued twelve-month price targets for Novavax's stock. Their forecasts range from $38.50 to $275.00. On average, they expect Novavax's share price to reach $175.79 in the next year. This suggests a possible upside of 38.1% from the stock's current price.
View analysts' price targets for Novavax
or view Wall Street analyst' top-rated stocks.

Are investors shorting Novavax?

Novavax saw a drop in short interest in the month of December. As of December 31st, there was short interest totaling 7,230,000 shares, a drop of 19.4% from the December 15th total of 8,970,000 shares. Based on an average daily trading volume, of 4,120,000 shares, the short-interest ratio is presently 1.8 days.
View Novavax's Short Interest
.

Who are some of Novavax's key competitors?

What other stocks do shareholders of Novavax own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novavax investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Moderna (MRNA), NVIDIA (NVDA), Tesla (TSLA), Palo Alto Networks (PANW), Advanced Micro Devices (AMD), Egalet (EGLT), Exact Sciences (EXAS) and Pfizer (PFE).

Who are Novavax's key executives?

Novavax's management team includes the following people:
  • Mr. Stanley Charles Erck, Pres, CEO & Director (Age 73, Pay $1.45M)
  • Mr. John A. Herrmann III, Exec. VP, Chief Legal Officer & Corp. Sec. (Age 55, Pay $865.02k)
  • Dr. Gregory M. Glenn, Pres of R&D (Age 67, Pay $1.06M)
  • Mr. John Joseph Trizzino, Exec. VP, Chief Bus. & Commercial Officer & Treasurer (Age 61, Pay $881.5k)
  • Mr. Gregory F. Covino, Exec. VP & CFO (Age 55)
  • Mr. Richard P. Crowley, Exec. VP & COO (Age 64)
  • Mr. Biegie Lee, Sr. VP & Chief Information Officer
  • Ms. Silvia Taylor M.B.A., MBA, Sr. VP of Investor Relations & Corp. Affairs
  • Ms. Erika S. Trahan, Associate Director of Investor & PR
  • Mr. Sven Andreasson M.B.A., Sr. VP of Corp. Devel. (Age 69)

What is Novavax's stock symbol?

Novavax trades on the NASDAQ under the ticker symbol "NVAX."

Who are Novavax's major shareholders?

Novavax's stock is owned by many different retail and institutional investors. Top institutional investors include Edge Wealth Management LLC (0.02%), Strategic Wealth Management Group LLC (0.02%), Diversified Trust Co (0.01%), XR Securities LLC (0.01%), Kestra Advisory Services LLC (0.00%) and Coastal Investment Advisors Inc. (0.00%). Company insiders that own Novavax stock include Gregory M Glenn, James F Young, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr, Rachel K King and Stanley C Erck.
View institutional ownership trends for Novavax
.

Which major investors are selling Novavax stock?

NVAX stock was sold by a variety of institutional investors in the last quarter, including Pacer Advisors Inc., Coastal Investment Advisors Inc., and XR Securities LLC. Company insiders that have sold Novavax company stock in the last year include Gregory M Glenn, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr, and Stanley C Erck.
View insider buying and selling activity for Novavax
or view top insider-selling stocks.

Which major investors are buying Novavax stock?

NVAX stock was bought by a variety of institutional investors in the last quarter, including Strategic Wealth Management Group LLC, Edge Wealth Management LLC, Diversified Trust Co, Kestra Advisory Services LLC, Exchange Traded Concepts LLC, Sowell Financial Services LLC, and CX Institutional. Company insiders that have bought Novavax stock in the last two years include Gregory M Glenn, James F Young, and Rachel K King.
View insider buying and selling activity for Novavax
or or view top insider-buying stocks.

How do I buy shares of Novavax?

Shares of NVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Novavax's stock price today?

One share of NVAX stock can currently be purchased for approximately $127.32.

How big of a company is Novavax?

Novavax has a market capitalization of $8.11 billion and generates $18.66 million in revenue each year. The biopharmaceutical company earns $-132,690,000.00 in net income (profit) each year or ($5.80) on an earnings per share basis. Novavax employs 522 workers across the globe.

What is Novavax's official website?

The official website for Novavax is www.novavax.com.

How can I contact Novavax?

Novavax's mailing address is 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. The biopharmaceutical company can be reached via phone at 240-268-2000 or via email at [email protected]

This page was last updated on 1/21/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.